联亚药业IPO：核心产品承压甚至需“倒贴”海外经销商 前十大外部股东关系紧密持股比例已超控股股东

Core Viewpoint - Nantong Lianya Pharmaceutical Co., Ltd. (Lianya Pharmaceutical) is facing significant challenges in its IPO journey, having previously attempted to list on the Sci-Tech Innovation Board and now shifting to the ChiNext Board, despite showing impressive revenue and net profit growth over the past three years. However, underlying issues such as product dependency, governance stability, and independence concerns are evident [1][10]. Financial Performance - Lianya Pharmaceutical reported revenues of 700 million yuan, 866 million yuan, and 441 million yuan for the years 2023, 2024, and the first half of 2025, respectively, with year-on-year growth rates of 27.33% and 23.67% for 2023 and 2024 [2][11]. - The net profit attributable to the parent company for the same periods was 116 million yuan, 260 million yuan, and 103 million yuan, with growth rates of 2.47% and 124.68% for 2023 and 2024 [2][11]. Product Dependency - Lianya Pharmaceutical's core business focuses on the research, production, and sales of complex drug formulations, with a significant reliance on its main product, Metoprolol Succinate Extended-Release Tablets, which accounted for approximately 54.69% of revenue in the first half of 2025, showing a trend of increasing dependency [2][11][12]. Market Dynamics - The company has faced a challenging pricing environment in the U.S. market, where its flagship product is caught in a cycle of price reductions, unstable market share, and negative revenue sharing, leading to losses of 11.03 million yuan in 2023 and 12.80 million yuan in 2024 [5][14]. - Despite a rapid increase in domestic revenue due to centralized procurement, foreign sales still represented a significant portion of total revenue, accounting for 58.41% in the first half of 2025 [4][13]. Governance and Control Issues - Recent changes in control structure, including the death of a key controlling shareholder and the cancellation of special voting rights, have raised concerns about governance stability and the potential for control disputes, especially as external shareholders now hold a significant influence over the company [7][9][16]. - The top ten external shareholders have complex relationships, with the second-largest shareholder holding 20.61% and combined holdings exceeding that of the controlling shareholder, indicating a potential alignment of interests that could impact governance [8][17].